PortalPublikationenMonitoring therapeutical intervention with ezetimibe using t...

Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis

Standard

Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis. / Graf, Kristof; Dietrich, Thore; Tachezy, Michael; Scholle, Frank-Detlef; Licha, Kai; Stawowy, Philipp; Grafe, Michael; Hauff, Peter; Fleck, Eckart.

in: MOL IMAGING, Jahrgang 7, Nr. 2, 2008, S. 68-76.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Graf, K, Dietrich, T, Tachezy, M, Scholle, F-D, Licha, K, Stawowy, P, Grafe, M, Hauff, P & Fleck, E 2008, 'Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis', MOL IMAGING, Jg. 7, Nr. 2, S. 68-76.

APA

Graf, K., Dietrich, T., Tachezy, M., Scholle, F-D., Licha, K., Stawowy, P., Grafe, M., Hauff, P., & Fleck, E. (2008). Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis. MOL IMAGING, 7(2), 68-76.

Vancouver

Graf K, Dietrich T, Tachezy M, Scholle F-D, Licha K, Stawowy P et al. Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis. MOL IMAGING. 2008;7(2):68-76.

Bibtex

@article{b2b919d4dc2f4fc4b9d6abf63c43e2a7,
title = "Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis",
abstract = "Ezetimibe (EZE), an inhibitor of cholesterol absorption, reduces atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice. The matrix protein ED-B fibronectin (ED-B) is upregulated in atherosclerotic lesions. Using a novel conjugate for near-infrared fluorescence (NIRF) imaging targeting ED-B, we studied the effect of EZE on plaque lesion formation in apoE(-/-) mice. ApoE(-/-) mice received EZE (5 mug/kg/d) or chow up to the age of 4, 6, and 8 months. NIRF imaging of aortic lesions was performed 24 hours after intravenous application ex vivo and in vivo. Plaque lesion formation was analyzed by histology and immunohistochemistry. Aortic lesion formation detected by Sudan staining and NIRF imaging was significantly reduced at 6 and 8 months (p < .001). Plaque areas determined by NIRF imaging significantly correlated with Sudan staining (p < .001). EZE treatment resulted in a significant reduction in plaque macrophage and ED-B immunoreactivity (both p < .05) in brachiocephalic lesions. There was a significant reduction in plaque size in brachiocephalic arteries in 8-month-old mice treated with EZE compared with mice during short-term treatment (p < .05), indicating EZE plaque regression. Targeted NIRF imaging showed a correlation to histologic lesion extension during therapeutical intervention in experimental atherosclerosis.",
keywords = "Animals, Anticholesteremic Agents, Aorta, Apolipoproteins E, Atherosclerosis, Azetidines, Diagnostic Imaging, Diet, Atherogenic, Disease Models, Animal, Fibronectins, Mice, Mice, Inbred C57BL, Mice, Knockout, Spectroscopy, Near-Infrared",
author = "Kristof Graf and Thore Dietrich and Michael Tachezy and Frank-Detlef Scholle and Kai Licha and Philipp Stawowy and Michael Grafe and Peter Hauff and Eckart Fleck",
year = "2008",
language = "English",
volume = "7",
pages = "68--76",
journal = "MOL IMAGING",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "2",

}

RIS

TY - JOUR

T1 - Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis

AU - Graf, Kristof

AU - Dietrich, Thore

AU - Tachezy, Michael

AU - Scholle, Frank-Detlef

AU - Licha, Kai

AU - Stawowy, Philipp

AU - Grafe, Michael

AU - Hauff, Peter

AU - Fleck, Eckart

PY - 2008

Y1 - 2008

N2 - Ezetimibe (EZE), an inhibitor of cholesterol absorption, reduces atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice. The matrix protein ED-B fibronectin (ED-B) is upregulated in atherosclerotic lesions. Using a novel conjugate for near-infrared fluorescence (NIRF) imaging targeting ED-B, we studied the effect of EZE on plaque lesion formation in apoE(-/-) mice. ApoE(-/-) mice received EZE (5 mug/kg/d) or chow up to the age of 4, 6, and 8 months. NIRF imaging of aortic lesions was performed 24 hours after intravenous application ex vivo and in vivo. Plaque lesion formation was analyzed by histology and immunohistochemistry. Aortic lesion formation detected by Sudan staining and NIRF imaging was significantly reduced at 6 and 8 months (p < .001). Plaque areas determined by NIRF imaging significantly correlated with Sudan staining (p < .001). EZE treatment resulted in a significant reduction in plaque macrophage and ED-B immunoreactivity (both p < .05) in brachiocephalic lesions. There was a significant reduction in plaque size in brachiocephalic arteries in 8-month-old mice treated with EZE compared with mice during short-term treatment (p < .05), indicating EZE plaque regression. Targeted NIRF imaging showed a correlation to histologic lesion extension during therapeutical intervention in experimental atherosclerosis.

AB - Ezetimibe (EZE), an inhibitor of cholesterol absorption, reduces atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice. The matrix protein ED-B fibronectin (ED-B) is upregulated in atherosclerotic lesions. Using a novel conjugate for near-infrared fluorescence (NIRF) imaging targeting ED-B, we studied the effect of EZE on plaque lesion formation in apoE(-/-) mice. ApoE(-/-) mice received EZE (5 mug/kg/d) or chow up to the age of 4, 6, and 8 months. NIRF imaging of aortic lesions was performed 24 hours after intravenous application ex vivo and in vivo. Plaque lesion formation was analyzed by histology and immunohistochemistry. Aortic lesion formation detected by Sudan staining and NIRF imaging was significantly reduced at 6 and 8 months (p < .001). Plaque areas determined by NIRF imaging significantly correlated with Sudan staining (p < .001). EZE treatment resulted in a significant reduction in plaque macrophage and ED-B immunoreactivity (both p < .05) in brachiocephalic lesions. There was a significant reduction in plaque size in brachiocephalic arteries in 8-month-old mice treated with EZE compared with mice during short-term treatment (p < .05), indicating EZE plaque regression. Targeted NIRF imaging showed a correlation to histologic lesion extension during therapeutical intervention in experimental atherosclerosis.

KW - Animals

KW - Anticholesteremic Agents

KW - Aorta

KW - Apolipoproteins E

KW - Atherosclerosis

KW - Azetidines

KW - Diagnostic Imaging

KW - Diet, Atherogenic

KW - Disease Models, Animal

KW - Fibronectins

KW - Mice

KW - Mice, Inbred C57BL

KW - Mice, Knockout

KW - Spectroscopy, Near-Infrared

M3 - SCORING: Journal article

C2 - 18706289

VL - 7

SP - 68

EP - 76

JO - MOL IMAGING

JF - MOL IMAGING

SN - 1535-3508

IS - 2

ER -